An orally administered butyrate‐releasing derivative reduces neutrophil recruitment and inflammation in dextran sulphate sodium‐induced murine colitis
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Background and Purpose: Butyrate has shown benefits in inflammatory bowel diseases. However, it is not often administered orally because of its rancid smell and unpleasant taste. The efficacy of a more palatable butyrate‐releasing derivative, N‐(1‐carbamoyl‐2‐phenylethyl) butyramide (FBA), was evaluated in a mouse model of colitis induced by dextran sodium sulphate (DSS). Experimental Approach: Male 10 week‐old BALB/c mice received DSS (2.5%) in drinking water (for 5 days) followed by DSS‐free water for 7 days (DSS group). Oral FBA administration (42.5 mg·kg−1) was started 7 days before DSS as preventive (P‐FBA), or 2 days after DSS as therapeutic (T‐FBA); both treatments lasted 19 days. One DSS‐untreated group received only tap water (CON). Key Results: FBA treatments reduced colitis symptoms and colon damage. P‐FBA and T‐FBA significantly decreased polymorphonuclear cell infiltration score compared with the DSS group. FBA reversed the imbalance between pro‐ and anti‐inflammatory cytokines (reducing inducible NOS protein expression, CCL2 and IL‐6 transcripts in colon and increasing TGFβ and IL‐10). Morever, P‐FBA and T‐FBA limited neutrophil recruitment (by expression and localization of the neutrophil granule protease Ly‐6G), restored deficiency of the butyrate transporter and improved intestinal epithelial integrity, preventing tight‐junction impairment (zonulin‐1 and occludin). FBA, similar to its parental compound sodium butyrate, inhibited histone deacetylase‐9 and restored H3 histone acetylation, exerting an anti‐inflammatory effect through NF‐κB inhibition and the up‐regulation of PPARγ. Conclusions and Implications: FBA reduces inflammatory intestinal damage in mice indicating its potential as a postbiotic derivative without the problems associated with the oral administration of sodium butyrate. Linked Articles: This article is part of a themed section on Principles of Pharmacological Research of Nutraceuticals. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.11/issuetoc
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic T reg Cell Homeostasis
Smith, P. M., Howitt, M. R., Panikov, N., Michaud, M., Gallini, C. A., Bohlooly-Y, M., Glickman, J. N., & Garrett, W. S. (2013) · Science · doi:10.1126/science.1241165 · Cited by 5,413
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00872.x · Cited by 3,625
Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43
Maslowski, K. M., Vieira, A. T., Ng, A., Kranich, J., Sierro, F., Yu, D., Schilter, H. C., Rolph, M. S., Mackay, F., Artis, D., et al. (2009) · Nature · doi:10.1038/nature08530 · Cited by 3,241 · cited 1×
“Among SCFAs, butyrate can influence chemotaxis of immune cells through FFA2 receptors, but this effect depends on the type of immune cells and butyrate concentration (Maslowski et al., 2009; Sina et al., 2009).”
BackgroundReview article: the role of butyrate on colonic function
HAMER, H. M., JONKERS, D., VENEMA, K., VANHOUTVIN, S., TROOST, F. J., & BRUMMER, R. ‐. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03562.x · Cited by 2,721
Singh, N., Gurav, A., Sivaprakasam, S., Brady, E., Padia, R., Shi, H., Thangaraju, M., Prasad, P. D., Manicassamy, S., Munn, D. H., et al. (2014) · Immunity · doi:10.1016/j.immuni.2013.12.007 · Cited by 2,368 · cited 2×
“, 2013) and together with GPR109A are considered the main butyrate targets involved in the suppression of colonic inflammation and carcinogenesis (Singh et al., 2014).”
BackgroundChang, P. V., Hao, L., Offermanns, S., & Medzhitov, R. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322269111 · Cited by 2,175 · cited 4×
“Following haematoxylin and eosin (H&E) staining, colon sections were analysed in a blinded manner for the evaluation of the histopathological score as previously described (Chang et al., 2014).”
BackgroundMethodResultInfluentialPeng, L., Li, Z.-R., Green, R. S., Holzmanr, I. R., & Lin, J. (2009) · The Journal of Nutrition · doi:10.3945/jn.109.104638 · Cited by 2,130 · cited 1×
“SCFAs modulate key epithelial cell functions that help tomaintain intestinal epithelial barrier integrity preventing injury (Peng et al., 2009).”
BackgroundAnimal Research: Reporting in vivo Experiments—The ARRIVE Guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.220 · Cited by 2,012
Potential beneficial effects of butyrate in intestinal and extraintestinal diseases
Canani, R. B. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i12.1519 · Cited by 1,381
Self-citationMcGrath, J. C., & Lilley, E. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12955 · Cited by 1,321
Tsou, C.-L., Peters, W., Si, Y., Slaymaker, S., Aslanian, A. M., Weisberg, S. P., Mack, M., & Charo, I. F. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29919 · Cited by 1,152 · cited 2×
“The role of the infiltration of immune cells in the inflammatory response during the development of colitis has already been assessed, as well as the efficacy of butyrate supplementation in limiting the recruitment of myeloid and lymphoid cells into the colonic mucosa (Tsou et al., 2007).”
BackgroundHou, J. K., Abraham, B., & El-Serag, H. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.44 · Cited by 1,009 · cited 2×
“…et al., 2004; Wedlake et al., 2014), other data had demonstrated an inverse association between intake of fruits and vegetables and risk of IBD (Amre et al., 2007), and more recently dietary intake and risk of developing IBD have been reviewed (Hou et al., 2011; Ananthakrishnan et al., 2013).”
BackgroundResultPPARγ as a new therapeutic target in inflammatory bowel diseases
Dubuquoy, L., Rousseaux, C., Thuru, X., Peyrin-Biroulet, L., Romano, O., Chavatte, P., Chamaillard, M., & Desreumaux, P. (2006) · Gut · doi:10.1136/gut.2006.093484 · Cited by 450 · cited 1×
“Genetic ablation of PPARγ resulted in increased susceptibility to experimental colitis in mice (Dubuquoy et al., 2006), and PPARγ protein expression is 60% lower in the inflamed colonic mucosa of UC patients than in controls (Dubuquoy et al., 2003).”
BackgroundButyrate modulates oxidative stress in the colonic mucosa of healthy humans
Hamer, H. M., Jonkers, D. M. A. E., Bast, A., Vanhoutvin, S. A. L. W., Fischer, M. A. J. G., Kodde, A., Troost, F. J., Venema, K., & Brummer, R.-J. M. (2009) · Clinical Nutrition · doi:10.1016/j.clnu.2008.11.002 · Cited by 400 · cited 1×
“The effects of SCFA, in particular butyrate, on intestinal diseases and their role on colonic functions are well-known (Hamer et al., 2008; Hamer et al., 2009; Canani et al., 2011).”
BackgroundVieira, E. L. M., Leonel, A. J., Sad, A. P., Beltrão, N. R. M., Costa, T. F., Ferreira, T. M. R., Gomes-Santos, A. C., Faria, A. M. C., Peluzio, M. C. G., Cara, D. C., et al. (2012) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2011.01.007 · Cited by 290 · cited 2×
“In fact, the beneficial effects of oral and topical administration of sodium butyrate on different models of DSS-induced colitis in mice have already been demonstrated (Vieira et al., 2012; Mishiro et al., 2013).”
Background
Cited by
Human gut microbiota/microbiome in health and diseases: a review
Gomaa, E. Z. (2020) · Antonie van Leeuwenhoek · doi:10.1007/s10482-020-01474-7 · Cited by 1,294
The gut microbiome: Relationships with disease and opportunities for therapy
Durack, J., & Lynch, S. V. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20180448 · Cited by 943
van de Wouw, M., Boehme, M., Lyte, J. M., Wiley, N., Strain, C., O'Sullivan, O., Clarke, G., Stanton, C., Dinan, T. G., & Cryan, J. F. (2018) · The Journal of Physiology · doi:10.1113/jp276431 · Cited by 789
“This was reversed by SCFA treatment, which is not surprising as SCFAs have previously been shown to restore intestinal permeability (Kelly et al. 2015; Tong et al. 2016; Simeoli et al. 2017).”
BackgroundChen, G., Ran, X., Li, B., Li, Y., He, D., Huang, B., Fu, S., Liu, J., & Wang, W. (2018) · eBioMedicine · doi:10.1016/j.ebiom.2018.03.030 · Cited by 580
“…piglets (Huang et al., 2015), promoting the recovering of intestinal wound healing through its positive effect on the tight junctions (Ma et al., 2012) and butyratereleasing derivativesmaintain proper Zo1 andOcln expression in the colons of patientswithDSS-induced colitis (Simeoli et al., 2017).”
BackgroundGut microbiota-derived short-chain fatty acids and their role in human health and disease
Mukhopadhya, I., & Louis, P. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01183-w · Cited by 501
Metadata
- Authors
- Simeoli, R., Mattace Raso, G., Pirozzi, C., Lama, A., Santoro, A., Russo, R., Montero‐Melendez, T., Berni Canani, R., Calignano, A., Perretti, M., & Meli, R.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2016-11-03
- Volume
- 174
- Issue
- 11
- Pages
- 1484-1496
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2528822221
- Cited by
- 134
- References
- 15
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.